Overview
Our team is primarily focused on clinical research in adolescent girls and women with bleeding disorders and in conducting clinical trials focused on hemophilia A with and without inhibitors. Our institution created the Atlanta Protocol which combines FVIII ITI with Hemlibra and this is under investigation in clinical trials.
- Emicizumab PUPs and Nuwiq ITI Study (co-PI), NCT04030052
- MOTIVATE Study (co-PI), NCT04023019
- ATHN 9: Severe VWD Study (co-PI), NCT03853486
- Mexico Inhibitor Study (recruitment in Mexico only)
Robert F. Sidonio, Jr. MD, MSc
Fun Fact: I love playing tennis and the ukulele.
Email: Robert.sidonio.jr@emory.edu
Megan Brown, MD, MSc (Assistant Professor, Pediatric Hematology/Oncology)
Education: Undergraduate, Michigan State University; MD, Michigan State University College of Human Medicine; MSc, Emory University; Residency (Pediatrics), University of Colorado-Denver; Fellowship, Emory University
Current Projects: Mexico Inhibitor Study and comparative effectiveness of heavy menstrual bleeding treatment.
Current Funding: National Hemophilia Foundation Takeda Clinical Fellowship
Fun Fact: I played college soccer and still love playing sports and being active.
Email: Megan.brown@choa.org
Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22(12):1328‐1337. doi:10.1080/13696998.2019.1669614
Sidonio RF, Zimowski KL. TFPI blockade: removing coagulation's brakes. Blood. 2019;134(22):1885‐1887. doi:10.1182/blood.2019002900
Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio RF Jr. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25(5):789‐796. doi:10.1111/hae.13819
Candy V, Whitworth H, Grabell J, Thibeault L, Harpell L, Bowman M, Good D, Hopman WM, Sidonio RF Jr., James PD. A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding. Blood Adv. 2018;2(20):2629‐2636. doi:10.1182/bloodadvances.2018023713
Anderst JD, Carpenter SL, Presley R, Berkoff MC, Wheeler AP, Sidonio RF Jr., Soucie JM. Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. Pediatrics. 2018;141(5):e20173485. doi:10.1542/peds.2017-3485
Grifols: Mexico Inhibitor Study (investigator-initiated) – 12/2017-12/2020
Goal: To estimate the prevalence of low and high titer inhibitors in a pilot population of moderate and severe hemophilia A patients in Mexico City, Mexico
Role: PI
ATHN 9 VWD (Shire) – 12/2017-12/2021
Goal: To characterize patients with symptomatic VWD and severe VWD in the United States enrolled in the ATHNdataset
Role: PI
Genentech/Octapharma: Emi Pups and Nuwiq ITI study (investigator-initiated) – 05/2018-05/2024
Goal: To assess the safety, immunogenicity, hemostatic efficacy and pharmacokinetics of Emicizumab in PUPs and MTPs with severe hemophilia A (baseline FVIII <1%) and to investigate the feasibility of a modified low dose FVIII ITI while on Emicizumab prophylaxis
Role: PI
Octapharma: MOTIVATE study (investigator-initiated) – 12/2018-12/2023
Goal: A prospective (and partly retrospective), observational, international study to capture different approaches to ITI (Emicizumab only, Bypassing agent only and the Atlanta Protocol)
Role: PI